- Home
- BOLT vs NIKI Comparison
BOLT vs NIKI Comparison
Compare BOLT & NIKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BOLT | NIKI |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 6.8M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BOLT | NIKI |
|---|---|---|
| Price | $3.35 | $5.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $34.00 | N/A |
| AVG Volume (30 Days) | 22.2K | ★ 246.1K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,695,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $133.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.07 | N/A |
| 52 Week Low | $3.13 | $5.68 |
| 52 Week High | $7.20 | $10.39 |
Technical Indicators
Market Signals| Indicator | BOLT | NIKI |
|---|---|---|
| Relative Strength Index (RSI) | 56.19 | 26.16 |
| Support Level | $3.87 | N/A |
| Resistance Level | $4.33 | $9.43 |
| Average True Range (ATR) | 0.31 | 0.73 |
| MACD | 0.03 | -0.15 |
| Stochastic Oscillator | 70.27 | 0.43 |
Price Performance
Historical ComparisonAbout BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.